Clinical Trial Detail

NCT ID NCT03719690
Title Safety and Efficacy of Tipifarnib in Head and Neck Cancer With HRAS Mutations and Impact of HRAS on Response to Therapy (AIM-HN/SEQ-HN)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Kura Oncology, Inc.
Indications

oral squamous cell carcinoma

head and neck squamous cell carcinoma

nasopharynx carcinoma

laryngeal squamous cell carcinoma

paranasal sinus cancer

pharynx squamous cell carcinoma

Therapies

Tipifarnib

Age Groups: adult senior

No variant requirements are available.